First Results from WHO Solidarity Trial
WHO concludes that subcutaneous IFN beta-1a is ineffective in hospitalized COVID-19 patientsFaron Pharmaceuticals Oy(“Faron” or the “Company”) Company announcement, 16 October 2020 at 1.35 PM (EEST) TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, today announces that the first results from the World Health Organization’s (WHO) Solidarity trial have been made available as a preprint at medRxiv[1] while under review for publication in a medical journal. The results show that subcutaneous interferon (IFN) beta-